Digital inhalers may help predict occurrence of acute exacerbations of COPD for patients in an ambulatory setting.

Research shows that digital inhalers equipped with remote monitoring capabilities may aid in predicting and identifying ...

In smokers with COPD, LABA+LAMA is more effective than LABA+ICS in preventing exacerbations, regardless of blood eosinophil count.

Between 14 days and 1 day out from an acute exacerbation of COPD, a digital inhaler measured significant drops in inhalation ...

The FDA recently approved mepolizumab for treating adults with inadequately controlled COPD and an eosinophilic phenotype, ...

It is becoming increasingly recognized that people with COPD have an elevated risk of serious CV events,1 discussed Hanania ...

Antibiotic demand for pneumonia and COPD in the top 20 countries showed high global consumption. Researchers conducted a ...

Regardless of chronic obstructive pulmonary disease status, finerenone mitigates clinical events and symptoms in patients with HFmrEF or HFpEF.

In the BOREAS and NOTUS trials, Dupixent cut the rate of exacerbations by 30% and 34%, respectively, and both those studies specifically enrolled patients with BEC levels of 300 cells/μL or above.

WebMD's COPD Health Center provides in-depth information on chronic obstructive pulmonary disease including symptoms, causes, treatment options, diagnosis, and tests.

These latest approvals come off the back of two successful trials: the BOREAS trial, which showed a 30% reduction in COPD exacerbations, and the NOTUS trial, which showed a reduction of 34%.

Rationale Chronic obstructive pulmonary disease (COPD) is associated with systemic inflammation and cardiovascular disease. Interaction between inflammatory cells and activated platelets is important ...